For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

One of the back­bones of can­cer med­i­cine is shut­ting down key can­cer-dri­ving path­ways to kill tu­mor cells. But for years, re­searchers have no­ticed hy­per­ac­ti­va­tion of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER